Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000951184 | SCV001097557 | likely benign | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2024-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004973197 | SCV005585134 | uncertain significance | Inborn genetic diseases | 2024-11-10 | criteria provided, single submitter | clinical testing | The c.328T>C (p.F110L) alteration is located in exon 3 (coding exon 3) of the EVC2 gene. This alteration results from a T to C substitution at nucleotide position 328, causing the phenylalanine (F) at amino acid position 110 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004751831 | SCV005366788 | likely benign | EVC2-related disorder | 2024-07-02 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |